On November 13, 2025, Cartesian Therapeutics, Inc. announced initial data from a Phase 2 trial showing that 100% of participants with systemic lupus erythematosus achieved low disease activity after treatment with Descartes-08. The company plans to expand the trial to myositis due to promising safety and efficacy results.